Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide

KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in ord...

Descripción completa

Detalles Bibliográficos
Autores principales: Asimakopoulou, Athina, Tzanela, Marinela, Koletti, Ageliki, Kontogeorgos, George, Tsagarakis, Stylianos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184761/
https://www.ncbi.nlm.nih.gov/pubmed/25356225
http://dx.doi.org/10.1002/ccr3.39
Descripción
Sumario:KEY CLINICAL MESSAGE: The clinical course of our patient, who sustained remission status for at least 18 months highlights the chance of long-term hormonal and tumor remission and demonstrates the efficacy and safety of discontinuation of temozolomide therapy. Prospective studies are required in order to define predictors of long-term remission of this promising therapeutic modality.

Ejemplares similares